Disease characteristics included of patients with CD
| Sex, women, n (%) | Serum cohort n=85 | Pax gene cohort n=20 |
| 41 (48.2) | 9 (45.0) | |
| Age, years, median (IQR) | 40.9 (26.0–53.8) | 30.6 (21.9–53.0) |
| Disease duration, years, median (IQR) | 11.4 (1.3–24.1) | 6.5 (1.1–25.1) |
| Timing endoscopic evaluation, weeks, median (IQR) | 25.3 (15.8–28.7) | 27.9 (26.0–29.1) |
| Anti-TNF agent, n (%) | ||
| Adalimumab | 39 (45.9) | 7 (35.0) |
| Infliximab | 46 (54.1) | 13 (65.0) |
| Endoscopic response, n (%) | ||
| Mucosal healing | 25 (29.4) | 10 (50.0) |
| Partial improvement | 41 (48.2) | 8 (40.0) |
| No improvement | 19 (22.4) | 2 (10.0) |
| Disease location, n (%) | ||
| Ileal disease (L1) | 28 (32.9) | 6 (30.0) |
| Colonic disease (L2) | 19 (22.4) | 4 (20.0) |
| Ileocolonic disease (L3) | 38 (44.7) | 10 (50.0) |
| Disease behaviour, n (%) | ||
| Non-stricturing non-penetrating (B1) | 33 (38.8) | 12 (60.0) |
| Stricturing (B2) | 37 (43.5) | 5 (25.0) |
| Penetrating (B3) | 15 (17.6) | 3 (15.0) |
| Perianal disease, n (%) | 19 (22.4) | 3 (15.0) |
CD, Crohn’s disease; TNF, tumour necrosis factor.